In conclusion, nab-PTX is an acceptable chemotherapeutic agent for aggressive breast cancers such as HER2-rich, luminal/HER2, and TNBC subtypes in a neoadjuvant setting. The gene discussed is ERBB2; the disease is breast cancer.